Nabriva Therapeutics AG (NBRV) Downgraded by ValuEngine to “Sell”
ValuEngine lowered shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
A number of other equities analysts have also recently commented on the company. Zacks Investment Research upgraded Nabriva Therapeutics AG from a sell rating to a hold rating and set a $12.00 target price for the company in a report on Tuesday, July 18th. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics AG and gave the stock a buy rating in a research note on Tuesday, July 11th. HC Wainwright reissued a buy rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research note on Friday, June 30th. Finally, Wedbush reissued an outperform rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $15.43.
Nabriva Therapeutics AG (NBRV) opened at 9.90 on Tuesday. The company’s market cap is $26.94 million. The company’s 50 day moving average price is $10.26 and its 200-day moving average price is $10.28. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/05/nabriva-therapeutics-ag-nbrv-downgraded-by-valuengine-to-sell.html.
In related news, Director George Harrison Talbot sold 325 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total transaction of $32,682.00. Following the completion of the sale, the director now directly owns 3,854 shares of the company’s stock, valued at approximately $387,558.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $10.94, for a total value of $143,609.38. Following the sale, the insider now directly owns 2,583,229 shares of the company’s stock, valued at $28,260,525.26. The disclosure for this sale can be found here. Insiders have sold a total of 205,115 shares of company stock valued at $2,252,057 over the last three months.
Several large investors have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $2,074,000. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $1,870,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Nabriva Therapeutics AG during the fourth quarter worth about $103,000. 56.72% of the stock is owned by hedge funds and other institutional investors.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.